Transcriptomics and proteomics reveal distinct biology for lymph node metastases and tumour deposits in colorectal cancer
Authors:
- Nelleke Pm BrouwerNelleke Pm Brouwer
- Loth WebbinkLWLoth Webbink
- Tariq S HaddadTariq S Haddad
- imCMS ConsortiumICimCMS Consortium
Open Access
- 4 October 2023
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 261 (4) , 401-412
Abstract
Both lymph node metastases (LNMs) and tumour deposits (TDs) are included in colorectal cancer (CRC) staging, although knowledge regarding their biological background is lacking. This study aimed to compare the biology of these prognostic features, which is essential for a better understanding of their role in CRC spread. Spatially resolved transcriptomic analysis using digital spatial profiling was performed on TDs and LNMs from 10 CRC patients using 1,388 RNA targets, for the tumour cells and tumour microenvironment. Shotgun proteomics identified 5,578 proteins in 12 different patients. Differences in RNA and protein expression were analysed, and spatial deconvolution was performed. Image‐based consensus molecular subtype (imCMS) analysis was performed on all TDs and LNMs included in the study. Transcriptome and proteome profiles identified distinct clusters for TDs and LNMs in both the tumour and tumour microenvironment segment, with upregulation of matrix remodelling, cell adhesion/motility, and epithelial–mesenchymal transition (EMT) in TDs (all p < 0.05). Spatial deconvolution showed a significantly increased abundance of fibroblasts, macrophages, and regulatory T‐cells (p < 0.05) in TDs. Consistent with a higher fibroblast and EMT component, imCMS classified 62% of TDs as poor prognosis subtype CMS4 compared to 36% of LNMs (p < 0.05). Compared to LNMs, TDs have a more invasive state involving a distinct tumour microenvironment and upregulation of EMT, which are reflected in a more frequent histological classification of TDs as CMS4. These results emphasise the heterogeneity of locoregional spread and the fact that TDs should merit more attention both in future research and during staging. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- University of Bern
- KWF Kankerbestrijding
This publication has 38 references indexed in Scilit:
- PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathwayOncotarget, 2016
- The MaxQuant computational platform for mass spectrometry-based shotgun proteomicsNature Protocols, 2016
- Targeting the Microenvironment in Advanced Colorectal CancerTrends in Cancer, 2016
- RETRACTED ARTICLE: SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironmentOncogene, 2016
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinomaBMC Cancer, 2014
- Identification of MXRA5 as a novel biomarker in colorectal cancerOncology Letters, 2012
- Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein KinasesScience, 2002
- Involvement of chemokine receptors in breast cancer metastasisNature, 2001
- The classification of cancer of the rectumThe Journal of Pathology and Bacteriology, 1932